Kasavi Ceyda
Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey.
Front Genet. 2022 Oct 19;13:971845. doi: 10.3389/fgene.2022.971845. eCollection 2022.
Ovarian cancer is the second most common gynecologic cancer and remains the leading cause of death of all gynecologic oncologic disease. Therefore, understanding the molecular mechanisms underlying the disease, and the identification of effective and predictive biomarkers are invaluable for the development of diagnostic and treatment strategies. In the present study, a differential co-expression network analysis was performed meta-analysis of three transcriptome datasets of serous ovarian adenocarcinoma to identify novel candidate biomarker signatures, i.e. genes and miRNAs. We identified 439 common differentially expressed genes (DEGs), and reconstructed differential co-expression networks using common DEGs and considering two conditions, i.e. healthy ovarian surface epithelia samples and serous ovarian adenocarcinoma epithelia samples. The modular analyses of the constructed networks indicated a co-expressed gene module consisting of 17 genes. A total of 11 biomarker candidates were determined through receiver operating characteristic (ROC) curves of gene expression of module genes, and miRNAs targeting these genes were identified. As a result, six genes (, , , , , and ), and two miRNAs (mir-147a, and mir-103a-3p) were suggested as novel candidate prognostic biomarkers for ovarian cancer. Further experimental and clinical validation of the proposed biomarkers could help future development of potential diagnostic and therapeutic innovations in ovarian cancer.
卵巢癌是第二常见的妇科癌症,仍然是所有妇科肿瘤疾病的主要死亡原因。因此,了解该疾病的分子机制以及识别有效和可预测的生物标志物对于制定诊断和治疗策略非常重要。在本研究中,对三个浆液性卵巢腺癌转录组数据集进行了差异共表达网络分析的荟萃分析,以识别新的候选生物标志物特征,即基因和微小RNA(miRNA)。我们鉴定出439个常见的差异表达基因(DEG),并使用常见的DEG并考虑两种情况(即健康卵巢表面上皮样本和浆液性卵巢腺癌上皮样本)重建了差异共表达网络。对构建网络的模块分析表明存在一个由17个基因组成的共表达基因模块。通过模块基因表达的受试者工作特征(ROC)曲线确定了总共11个候选生物标志物,并鉴定了靶向这些基因的miRNA。结果,六个基因(,,,,,和)以及两个miRNA(mir-147a和mir-103a-3p)被建议作为卵巢癌新的候选预后生物标志物。对所提出的生物标志物进行进一步的实验和临床验证可能有助于卵巢癌潜在诊断和治疗创新的未来发展。